Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome - Full Text View

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome (NAS)

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Johns Hopkins University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00510016

Purpose

To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.

Condition	Intervention	Phase
Neonatal Abstinence Syndrome	Drug: Clonidine HCL	Phase II

ChemIDplus related topics:

Methadone Methadone hydrochloride Clonidine Clonidine hydrochloride Diacetylmorphine Diacetylmorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Length of treatment for neonatal abstinence syndrome [ Time Frame: duration of the treatment ]

Enrollment:	80
Study Start Date:	July 2002
Study Completion Date:	December 2005

Arms	Assigned Interventions
Clonidine treatment: Experimental Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.	Drug: Clonidine HCL Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm

Eligibility

Ages Eligible for Study:	up to 14 Days
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

neonates born at gestational age of 35 weeks or greater
neonates aged 0 to 14 days
prenatally exposed to opioids
severe NAS defined as 2 consecutive modified Finnegan Scores (MFS) > or = 9

Exclusion Criteria:

< 35 weeks gestational age
Intrauterine growth retardation defined as <5%tile of gestational age
postnatal treatment with barbiturates or benzodiazepines,
major congenital anomalies
major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications.
breastfed infants

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00510016

Locations


United States, Maryland
	Johns Hopkins Medical Institutions
	Baltimore, Maryland, United States, 21287-3200

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Johns Hopkins University

Investigators


Principal Investigator:	Estelle B Gauda, M.D.	Johns Hopkins Medical Institutions

More Information

Publications:

Hoder EL, Leckman JF, Poulsen J, Caruso KA, Ehrenkranz RA, Kleber HD, Cohen DJ. Clonidine treatment of neonatal narcotic abstinence syndrome. Psychiatry Res. 1984 Nov;13(3):243-51.

Gold MS, Pottash AL, Extein I, Kleber HD. Clonidine and opiate withdrawal. Lancet. 1980 Nov 15;2(8203):1078-9. No abstract available.

Study ID Numbers:	1R21DA016288-01A1, 1R21DA016288-01A1
First Received:	July 31, 2007
Last Updated:	July 31, 2007
ClinicalTrials.gov Identifier:	NCT00510016
Health Authority:	United States: Food and Drug Administration

Keywords provided by National Institute on Drug Abuse (NIDA):

infants

opioid withdrawal

abstinence syndrome

methadone

heroin

Study placed in the following topic categories:

Methadone

Heroin

Mental Disorders

Neonatal Abstinence Syndrome

Clonidine

Substance-Related Disorders

Disorders of Environmental Origin

Infant, Newborn, Diseases

Additional relevant MeSH terms:

Sympatholytics

Neurotransmitter Agents

Disease

Adrenergic alpha-Agonists

Adrenergic Agents

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Cardiovascular Agents

Antihypertensive Agents

Adrenergic Agonists

Pharmacologic Actions

Pathologic Processes

Autonomic Agents

Sensory System Agents

Therapeutic Uses

Syndrome

Analgesics

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on September 05, 2008